April 26, 2011 - Vectomega Omega-3 Extract From Salmon Superior to Fish and Krill Oil

EUROPHARMA’S NOVEL OMEGA-3 EXTRACT FROM SALMON SUPERIOR TO FISH AND KRILL OIL

Vectomega’s highly absorbable Omega-3s delivered by phospholipids—NOT triglycerides

GREEN BAY, WI, April 26, 2011—Fish oil has long been the standard for delivery of Omega-3 fatty acids, which are bound to triglycerides. However, Nutrition Business Journal reports that krill oil sales are dramatically increasing and outpacing fish oil in percentage of growth, due to the fact that the Omega-3 fatty acids are attached to superior delivery phospholipids—not triglycerides. They clearly document the emergence of phospholipids versus triglycerides as a superior carrier of DHA and EPA (important Omega-3 fatty acids) because of better absorption. However, a patented process from Europe called “Vectorization” has for the first time produced a fish (salmon) source Omega-3 product, naturally attached to phospholipids, enhancing the absorption of the Omega-3 fatty acids up to 50-fold over fish oil.^1,2,3 The product, called Vectomega^®, is the first fish source Omega-3 fatty acid delivered by phospholipids, and is distributed exclusively by EuroPharma, Inc.^®

Though krill oil is better absorbed than triglyceride fish oils, many view it as a problematic source. In early May, 2010, retail supplement giant Whole Foods announced withdrawal of krill oil from its stores, citing “Krill are an important source of food for marine animals including penguins, seals, and whales in the Antarctic. Declines of some predator populations in the areas where the krill fishery operates suggest that fishery management needs to better understand how to evaluate the prey requirements of other marine species in order to set sustainable catch levels for krill.”

Krill fishing is now banned off the coasts of California, Oregon and Washington.⁴ Another concern is that krill fight global warming. They feed on phytoplankton at the surface of the ocean, and then sink to the depths to digest food and deposit carbon-rich waste on the ocean floor. This process transports an amount of carbon equivalent to the annual emissions of 35 million cars.⁵

Additionally, extraction processes reported to be used in extraction of Omega-3s from krill, which are very small and encased in a shell, have often involved the use of various solvents. Some solvents (for example, hexane) can have adverse health impacts at higher levels and trigger problems in individuals with multiple chemical sensitivities even at very low levels. Vectorization uses only enzymes and a cold water flush to produce Vectomega from salmon. The process involves no heat, no chemicals, and no solvents. And unlike both fish and krill oil, Vectomega is not an oil. It is an Omega-3 phospholipid complex from salmon. Since it is not an oil, Vectomega is very stable, and does not have the same problematic rancidity issues of fish oil. Additionally, Vectomega does not cause unpleasant regurgitation (fish burps) that is common with fish oils.

Vectomega is the result of a collaboration of the French government and the University of Nancy (France) for a research endeavor. In 2001, the French government, in conjunction with the National Interprofessional Office for Sea Products and Aquaculture, asked researchers to investigate potential uses for salmon.  This governmental research project gave rise to the patented Vectorization process and Vectomega.

According to EuroPharma’s founder and president, Terry Lemerond, “Vectorization is important for many reasons. First, all the salmon used are food-grade, sustainably harvested in clean, deep water fjords of Norway and Scotland. These are fish that are meant to be eaten, and aren’t “junk fish” like many used in oils. Secondly, because of the gentle nature of the Vectorization process, the EPA and DHA remain bioidentical to those found in the human brain (unlike fish oils), and third, because the Omega-3 fatty acids are bound to phospholipids rather than triglycerides, they are up to 50 times better absorbed than the Omega-3 fatty acids in fish oil. And last, but certainly not least, consumers do not have to take 8 to 12 fish oil capsules or spoonfuls of liquid oil to meet their daily Omega-3 needs. Only one or two small Vectomega tablets per day is equal in Omega-3 effects to 4 to 6 grams of fish oil⁶ , or a large serving of fresh salmon.”

EuroPharma, Inc. is the exclusive distributor of Vectomega in the U.S. through both the health food store and professional distribution channels. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. Terry Lemerond, founder and president of EuroPharma, is well-known for innovation, as he is credited as the first to introduce glucosamine sulfate, standardized Ginkgo biloba, and the award winning natural pain product, Curamin^®, to the U.S. natural products market. At EuroPharma, Our Passion is Your Health™.  For more information on EuroPharma, visit www.EuroPharmaUSA.com.

References

1. Linder M, Jacques F, Parmentier M, Pierre R. Procede d’obtention d’une huile et d’un hydrolysat de proteins a partir d’une source marine de tissus proteiques et huile et hydrolysat de proteins obtenus par mise en oeuvre de ce procede. French patent 2835703. August 2, 2002.
2. Pamentier M, Al Sayed Mahoud C, Linder M, Fanni J, et al. Polar lipids: n-3 PUFA carriers for membranes and brain: nutritional interest and emerging process. Oleagineux, Corps Gras, Lipids. 2007;14(3):224-9.
3. Analysis at the Nancy-Université, INPL-ENSAIA; Laboratoire de Science et Génie Alimentaires, Vandoeuvre-les-Nancy, France.
4. MSNBC. Federal Ban on Krill Fishing Off West Coast. 7/13/2009. Available at: http://www.msnbc.msn.com/id/31896169/ns/us_news-environment Accessed 4/5/11.
5. The Times Higher Education. Antarctic krill sink enough carbon dioxide to neutralise 35 million cars. 2/9/2006. Available at: http://www.timeshighereducation.co.uk/story.asp?storyCode=201326§ioncode=26. Accessed 4/5/2011.
6. Arer M, Duclaut J. Assessment of biological and clinical effects of Vectomega among healthy volunteers. 2006; Clinique Mèdical. Rennes et St Etienne, France. Pre-publication data.